These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
321 related articles for article (PubMed ID: 24994714)
1. AMPK reverses the mesenchymal phenotype of cancer cells by targeting the Akt-MDM2-Foxo3a signaling axis. Chou CC; Lee KH; Lai IL; Wang D; Mo X; Kulp SK; Shapiro CL; Chen CS Cancer Res; 2014 Sep; 74(17):4783-95. PubMed ID: 24994714 [TBL] [Abstract][Full Text] [Related]
2. miR-4448/Girdin/Akt/AMPK axis inhibits EZH2-mediated EMT and tumorigenesis in small-cell lung cancer. Koyama N; Ishikawa Y; Ohta H; Aoki T; Kyoyama H; Aoshiba K; Uematsu K Cancer Med; 2024 Oct; 13(19):e70093. PubMed ID: 39400978 [TBL] [Abstract][Full Text] [Related]
3. Targeting energy metabolic and oncogenic signaling pathways in triple-negative breast cancer by a novel adenosine monophosphate-activated protein kinase (AMPK) activator. Lee KH; Hsu EC; Guh JH; Yang HC; Wang D; Kulp SK; Shapiro CL; Chen CS J Biol Chem; 2011 Nov; 286(45):39247-58. PubMed ID: 21917926 [TBL] [Abstract][Full Text] [Related]
4. Inhibition of epithelial to mesenchymal transition by E-cadherin up-regulation via repression of slug transcription and inhibition of E-cadherin degradation: dual role of scaffold/matrix attachment region-binding protein 1 (SMAR1) in breast cancer cells. Adhikary A; Chakraborty S; Mazumdar M; Ghosh S; Mukherjee S; Manna A; Mohanty S; Nakka KK; Joshi S; De A; Chattopadhyay S; Sa G; Das T J Biol Chem; 2014 Sep; 289(37):25431-44. PubMed ID: 25086032 [TBL] [Abstract][Full Text] [Related]
5. Paclitaxel suppresses the viability of breast tumor MCF7 cells through the regulation of EF1α and FOXO3a by AMPK signaling. Kim JH; Lee JO; Kim N; Lee HJ; Lee YW; Kim HI; Kim SJ; Park SH; Kim HS Int J Oncol; 2015 Nov; 47(5):1874-80. PubMed ID: 26397839 [TBL] [Abstract][Full Text] [Related]
6. Metformin mediated reversal of epithelial to mesenchymal transition is triggered by epigenetic changes in E-cadherin promoter. Banerjee P; Surendran H; Chowdhury DR; Prabhakar K; Pal R J Mol Med (Berl); 2016 Dec; 94(12):1397-1409. PubMed ID: 27534967 [TBL] [Abstract][Full Text] [Related]
7. Mouse double minute 2 (MDM2) upregulates Snail expression and induces epithelial-to-mesenchymal transition in breast cancer cells in vitro and in vivo. Lu X; Yan C; Huang Y; Shi D; Fu Z; Qiu J; Yin Y Oncotarget; 2016 Jun; 7(24):37177-37191. PubMed ID: 27184007 [TBL] [Abstract][Full Text] [Related]
8. Insulin receptor substrate 2 and FoxO3a signalling are involved in E-cadherin expression and transforming growth factor-β1-induced repression in kidney epithelial cells. Carew RM; Browne MB; Hickey FB; Brazil DP FEBS J; 2011 Sep; 278(18):3370-80. PubMed ID: 21777391 [TBL] [Abstract][Full Text] [Related]
9. Activation of AMPK inhibits cervical cancer cell growth through AKT/FOXO3a/FOXM1 signaling cascade. Yung MM; Chan DW; Liu VW; Yao KM; Ngan HY BMC Cancer; 2013 Jul; 13():327. PubMed ID: 23819460 [TBL] [Abstract][Full Text] [Related]
10. Antagonism of miR-21 reverses epithelial-mesenchymal transition and cancer stem cell phenotype through AKT/ERK1/2 inactivation by targeting PTEN. Han M; Liu M; Wang Y; Chen X; Xu J; Sun Y; Zhao L; Qu H; Fan Y; Wu C PLoS One; 2012; 7(6):e39520. PubMed ID: 22761812 [TBL] [Abstract][Full Text] [Related]
11. Metformin suppresses expression of the selenoprotein P gene via an AMP-activated kinase (AMPK)/FoxO3a pathway in H4IIEC3 hepatocytes. Takayama H; Misu H; Iwama H; Chikamoto K; Saito Y; Murao K; Teraguchi A; Lan F; Kikuchi A; Saito R; Tajima N; Shirasaki T; Matsugo S; Miyamoto K; Kaneko S; Takamura T J Biol Chem; 2014 Jan; 289(1):335-45. PubMed ID: 24257750 [TBL] [Abstract][Full Text] [Related]
12. FOXO3a modulates WNT/β-catenin signaling and suppresses epithelial-to-mesenchymal transition in prostate cancer cells. Liu H; Yin J; Wang H; Jiang G; Deng M; Zhang G; Bu X; Cai S; Du J; He Z Cell Signal; 2015 Mar; 27(3):510-8. PubMed ID: 25578861 [TBL] [Abstract][Full Text] [Related]
13. DNMT3B overexpression by deregulation of FOXO3a-mediated transcription repression and MDM2 overexpression in lung cancer. Yang YC; Tang YA; Shieh JM; Lin RK; Hsu HS; Wang YC J Thorac Oncol; 2014 Sep; 9(9):1305-15. PubMed ID: 25122426 [TBL] [Abstract][Full Text] [Related]
14. Opposite regulation of MDM2 and MDMX expression in acquisition of mesenchymal phenotype in benign and cancer cells. Slabáková E; Kharaishvili G; Smějová M; Pernicová Z; Suchánková T; Remšík J; Lerch S; Straková N; Bouchal J; Král M; Culig Z; Kozubík A; Souček K Oncotarget; 2015 Nov; 6(34):36156-71. PubMed ID: 26416355 [TBL] [Abstract][Full Text] [Related]
15. Forkhead Box Protein C2 Promotes Epithelial-Mesenchymal Transition, Migration and Invasion in Cisplatin-Resistant Human Ovarian Cancer Cell Line (SKOV3/CDDP). Li C; Ding H; Tian J; Wu L; Wang Y; Xing Y; Chen M Cell Physiol Biochem; 2016; 39(3):1098-110. PubMed ID: 27562816 [TBL] [Abstract][Full Text] [Related]
16. Constitutively nuclear FOXO3a localization predicts poor survival and promotes Akt phosphorylation in breast cancer. Chen J; Gomes AR; Monteiro LJ; Wong SY; Wu LH; Ng TT; Karadedou CT; Millour J; Ip YC; Cheung YN; Sunters A; Chan KY; Lam EW; Khoo US PLoS One; 2010 Aug; 5(8):e12293. PubMed ID: 20808831 [TBL] [Abstract][Full Text] [Related]
17. Metformin reverses mesenchymal phenotype of primary breast cancer cells through STAT3/NF-κB pathways. Esparza-López J; Alvarado-Muñoz JF; Escobar-Arriaga E; Ulloa-Aguirre A; de Jesús Ibarra-Sánchez M BMC Cancer; 2019 Jul; 19(1):728. PubMed ID: 31337349 [TBL] [Abstract][Full Text] [Related]
18. Activation of FOXO3a by the green tea polyphenol epigallocatechin-3-gallate induces estrogen receptor alpha expression reversing invasive phenotype of breast cancer cells. Belguise K; Guo S; Sonenshein GE Cancer Res; 2007 Jun; 67(12):5763-70. PubMed ID: 17575143 [TBL] [Abstract][Full Text] [Related]
19. AMP-activated protein kinase enhances the expression of muscle-specific ubiquitin ligases despite its activation of IGF-1/Akt signaling in C2C12 myotubes. Tong JF; Yan X; Zhu MJ; Du M J Cell Biochem; 2009 Oct; 108(2):458-68. PubMed ID: 19639604 [TBL] [Abstract][Full Text] [Related]
20. Nimotuzumab inhibits epithelial-mesenchymal transition in prostate cancer by targeting the Akt/YB-1/AR axis. Hu S; Duan YX; Zhou Q; Wang Y; Lu Q IUBMB Life; 2019 Jul; 71(7):928-941. PubMed ID: 30907986 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]